MatriDerm® nerve wrap to repair cut sensory nerves in the hand and fingers.

Nerve Grafting Using MATRIderm® in Traumatic Digital Nerve Injuries: a Randomized, Single-center, Controlled Study

Not applicable Interventional Centre Hospitalier Universitaire de Nice · NCT07292415

We will try wrapping a stitched hand or finger sensory nerve with MatriDerm® to see if it improves healing and reduces scarring for people aged 16–75 with traumatic nerve injuries.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment70 (estimated)
Ages16 Years to 75 Years
SexAll
SponsorCentre Hospitalier Universitaire de Nice Academic / other
Locations1 site (Nice, Alpes Maritimes)
Trial IDNCT07292415 on ClinicalTrials.gov

What this trial studies

This randomized, single-center controlled trial at CHU de Nice compares standard epineural suture repair to the same repair with a 1 mm MatriDerm® collagen-elastin matrix wrapped along the repaired nerve. Eligible patients are 16–75 years old with palm or finger wounds causing partial (>50%) or total sensory nerve loss that can be directly sutured under regional anesthesia and magnification. Postoperative care may include up to two weeks of immobilization if needed, and patients are followed clinically with a key visit at one year to measure sensation, pain, and neuroma or scarring outcomes. The study measures whether adding MatriDerm® improves sensory recovery and reduces painful neuroma formation compared with standard repair.

Who should consider this trial

Good fit: Ideal candidates are people aged 16–75 with palm or finger wounds causing significant sensory nerve loss who are eligible for direct epineural suture repair and can attend a one-year follow-up at CHU de Nice.

Not a fit: Patients with pre-existing sensory disorders or prior nerve injury in the same hand, active hand infection, known hypersensitivity to bovine proteins, or who are pregnant or breastfeeding are excluded and unlikely to benefit from this procedure.

Why it matters

Potential benefit: If successful, MatriDerm® wrapping could improve sensory recovery and reduce painful neuromas and scar-related problems after repaired digital nerve injuries.

How similar studies have performed: MatriDerm® is well established for skin and soft-tissue reconstruction and some preclinical and early clinical work supports collagen matrices for nerve support, but using MatriDerm® specifically as a nerve wrap is relatively novel with limited clinical evidence.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patient aged 16 to 75
2. Patient with a palm or finger wound with sensory nerve damage (partial \>50% or total)
3. Indication for repair by direct suture in the operating room
4. Possibility of attending a follow-up visit after 1 year
5. Patient affiliated with a social security system
6. Patient who has given their written consent after receiving written and oral information

Exclusion Criteria:

1. Pre-existing sensory disorders
2. History of nerve damage in the affected hand
3. Known hypersensitivity to bovine proteins
4. Active infection in the affected hand
5. Patient protected by law under guardianship or curatorship, or unable to participate in a clinical study MATRINERVE 24-PP-12 Version No. 1.0 dated July 22, 2025 Page 8 of 40 clinical trial under Article L. 1121-16 of the French Public Health Code
6. Pregnant or breastfeeding women of childbearing age

Where this trial is running

Nice, Alpes Maritimes

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions This Study is Testing the Use of MatriDerm
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.